Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 597

1.

A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: a tri-state transplant consortium study.

Hassoun H, Bayer R, Devlin S, Gentile T, Becker M, O'Dweyer K, Lesser M, Landau H, Chung D, Giralt S.

Leuk Lymphoma. 2020 Jan 19:1-3. doi: 10.1080/10428194.2019.1672058. [Epub ahead of print] No abstract available.

PMID:
31957517
2.

Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients.

Maples KT, Maloy M, Devlin S, Lin A, DeRespiris L, Griffin M, Lau C, Proli AJ, Papanicolaou GA, Seo SK, Barker JN, Perales MA, Giralt SA, Bhatt V.

Bone Marrow Transplant. 2020 Jan 14. doi: 10.1038/s41409-020-0785-9. [Epub ahead of print] No abstract available.

PMID:
31937928
3.

Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin.

Politikos I, Lavery JA, Hilden P, Cho C, Borrill T, Maloy MA, Giralt SA, van den Brink MRM, Perales MA, Barker JN.

Blood Adv. 2020 Jan 14;4(1):191-202. doi: 10.1182/bloodadvances.2019000836.

4.

Incidence and Risk Factors for Acute and Chronic Kidney Injury After Adult Cord Blood Transplantation.

Gutgarts V, Sathick IJ, Zheng J, Politikos I, Devlin SM, Maloy MA, Giralt SA, Scordo M, Bhatt V, Glezerman I, Muthukumar T, Jaimes EA, Barker JN.

Biol Blood Marrow Transplant. 2020 Jan 3. pii: S1083-8791(19)31738-0. doi: 10.1016/j.bbmt.2019.12.768. [Epub ahead of print]

PMID:
31911259
5.

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.

Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME.

J Clin Oncol. 2019 Dec 20:JCO1903011. doi: 10.1200/JCO.19.03011. [Epub ahead of print]

PMID:
31860405
6.

Lactose drives Enterococcus expansion to promote graft-versus-host disease.

Stein-Thoeringer CK, Nichols KB, Lazrak A, Docampo MD, Slingerland AE, Slingerland JB, Clurman AG, Armijo G, Gomes ALC, Shono Y, Staffas A, Burgos da Silva M, Devlin SM, Markey KA, Bajic D, Pinedo R, Tsakmaklis A, Littmann ER, Pastore A, Taur Y, Monette S, Arcila ME, Pickard AJ, Maloy M, Wright RJ, Amoretti LA, Fontana E, Pham D, Jamal MA, Weber D, Sung AD, Hashimoto D, Scheid C, Xavier JB, Messina JA, Romero K, Lew M, Bush A, Bohannon L, Hayasaka K, Hasegawa Y, Vehreschild MJGT, Cross JR, Ponce DM, Perales MA, Giralt SA, Jenq RR, Teshima T, Holler E, Chao NJ, Pamer EG, Peled JU, van den Brink MRM.

Science. 2019 Nov 29;366(6469):1143-1149. doi: 10.1126/science.aax3760.

PMID:
31780560
7.

Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.

Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash MH, Sahebi F, Somlo G, Rowley S, Vogl DT, Vesole DH, Pasquini M, Stadtmauer E.

Biol Blood Marrow Transplant. 2019 Nov 19. pii: S1083-8791(19)30785-2. doi: 10.1016/j.bbmt.2019.11.018. [Epub ahead of print]

PMID:
31756536
8.

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.

Prockop S, Doubrovina E, Suser S, Heller G, Barker J, Dahi P, Perales MA, Papadopoulos E, Sauter C, Castro-Malaspina H, Boulad F, Curran KJ, Giralt S, Gyurkocza B, Hsu KC, Jakubowski A, Hanash AM, Kernan NA, Kobos R, Koehne G, Landau H, Ponce D, Spitzer B, Young JW, Behr G, Dunphy M, Haque S, Teruya-Feldstein J, Arcila M, Moung C, Hsu S, Hasan A, O'Reilly RJ.

J Clin Invest. 2020 Jan 6. pii: 121127. doi: 10.1172/JCI121127. [Epub ahead of print]

9.

Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34+ selected graft.

Lin RJ, Sanchez M, Abbi K, Devlin SM, Jakubowski AA, Papadopoulos EB, Barker JN, Tamari R, Young JW, Gyurkocza B, Ponce DM, Dahi PB, Maloy MA, Giralt SA, Perales MA, Castro-Malaspina H.

Bone Marrow Transplant. 2019 Oct 23. doi: 10.1038/s41409-019-0723-x. [Epub ahead of print] No abstract available.

PMID:
31645667
10.

Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease.

Montoro J, Ceberio I, Hilden P, Maloy MA, Barker J, Castro-Malaspina H, Dahi P, Koehne G, Perales MA, Ponce D, Sauter C, Shaffer B, Tamari R, Young JW, Giralt SA, O'Reilly RJ, Jakubowski AA, Papadopoulos EB.

Biol Blood Marrow Transplant. 2020 Feb;26(2):323-332. doi: 10.1016/j.bbmt.2019.10.003. Epub 2019 Oct 13.

PMID:
31618690
11.

Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.

Lin A, Maloy M, Su Y, Bhatt V, DeRespiris L, Griffin M, Lau C, Proli A, Barker J, Shaffer B, Giralt SA, Jakubowski AA, Papadopoulos EB, Papanicolaou GA, Seo SK, Perales MA.

Transpl Infect Dis. 2019 Dec;21(6):e13187. doi: 10.1111/tid.13187. Epub 2019 Oct 21.

PMID:
31585500
12.

Reduction of Opioid Use by Acupuncture in Patients Undergoing Hematopoietic Stem Cell Transplantation: Secondary Analysis of a Randomized, Sham-Controlled Trial.

Deng G, Giralt S, Chung DJ, Landau H, Siman J, Li QS, Lapen K, Mao JJ.

Pain Med. 2019 Sep 9. pii: pnz190. doi: 10.1093/pm/pnz190. [Epub ahead of print]

PMID:
31498394
13.

Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma.

Bryant AR, Hilden P, Giralt S, Chung DJ, Maloy M, Landau H, Landgren O, Scordo M, Shah G, Smith EL, O'Reilly RJ, Perales MA, Koehne G.

Biol Blood Marrow Transplant. 2020 Jan;26(1):58-65. doi: 10.1016/j.bbmt.2019.08.023. Epub 2019 Sep 5.

PMID:
31493537
14.

Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies.

Lin RJ, Elko TA, Devlin SM, Shahrokni A, Jakubowski AA, Dahi PB, Perales MA, Tamari R, Shaffer BC, Sauter CS, Papadopoulos EB, Gyurkocza B, Korc-Grodzicki B, Barker JN, Maloy MA, Giralt SA.

Bone Marrow Transplant. 2020 Jan;55(1):157-164. doi: 10.1038/s41409-019-0654-6. Epub 2019 Aug 30.

PMID:
31471572
15.

Fast deep water warming of a subtropical crater lake.

Cardoso-Mohedano JG, Sanchez-Cabeza JA, Ruiz-Fernández AC, Pérez-Bernal LH, Lima-Rego J, Giralt S.

Sci Total Environ. 2019 Nov 15;691:1353-1361. doi: 10.1016/j.scitotenv.2019.07.183. Epub 2019 Jul 13.

PMID:
31466213
16.

Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis.

Landau H, Lahoud O, Devlin S, Lendvai N, Chung DJ, Dogan A, Landgren CO, Giralt S, Hassoun H.

Biol Blood Marrow Transplant. 2020 Jan;26(1):204-208. doi: 10.1016/j.bbmt.2019.08.016. Epub 2019 Aug 22.

PMID:
31446197
17.

CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy.

Hill JA, Giralt S, Torgerson TR, Lazarus HM.

Blood Rev. 2019 Nov;38:100596. doi: 10.1016/j.blre.2019.100596. Epub 2019 Aug 7. Review.

PMID:
31416717
18.

Measurement of the DNA alkylating agents busulfan and melphalan in human plasma by mass spectrometry.

Schofield RC, Landau HJ, Giralt SA, Shah GL, Scordo M, Lin A, Zanutto E, Ramanathan LV, Pessin MS, Carlow DC.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Sep 1;1125:121711. doi: 10.1016/j.jchromb.2019.121711. Epub 2019 Jul 4.

PMID:
31376591
19.

CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.

Sauter CS, Senechal B, Rivière I, Ni A, Bernal Y, Wang X, Purdon T, Hall M, Singh AN, Szenes VZ, Yoo S, Dogan A, Wang Y, Moskowitz CH, Giralt S, Matasar MJ, Perales MA, Curran KJ, Park J, Sadelain M, Brentjens RJ.

Blood. 2019 Aug 15;134(7):626-635. doi: 10.1182/blood.2018883421. Epub 2019 Jul 1.

PMID:
31262783
20.

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.

Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR.

Clin Cancer Res. 2019 Aug 15;25(16):5143-5155. doi: 10.1158/1078-0432.CCR-18-3988. Epub 2019 Jun 28.

PMID:
31253630
21.

Feasibility of a patient-reported, electronic geriatric assessment tool in hematopoietic cell transplantation - a single institution pilot study.

Lin RJ, Dahi PB, Shahrokni A, Sarraf S, Korc-Grodzicki B, Devlin SM, Maloy MA, Shah GL, Jakubowski AA, Giralt SA.

Leuk Lymphoma. 2019 Dec;60(13):3308-3311. doi: 10.1080/10428194.2019.1630621. Epub 2019 Jun 21. No abstract available.

PMID:
31226901
22.

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S.

Lancet Oncol. 2019 Jun;20(6):e302-e312. doi: 10.1016/S1470-2045(19)30309-2. Review. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31162104
23.

Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.

Jain T, Sauter CS, Shah GL, Maloy MA, Chan J, Scordo M, Avecilla ST, Batlevi Y, Dahi PB, Batlevi CW, Lia Palomba M, Giralt SA, Perales MA.

Leukemia. 2019 Oct;33(10):2540-2544. doi: 10.1038/s41375-019-0476-y. Epub 2019 May 21. No abstract available.

PMID:
31114023
24.

Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis.

Barker JN, Boughan K, Dahi PB, Devlin SM, Maloy MA, Naputo K, Mazis CM, Davis E, Nhaissi M, Wells D, Cooper C, Ponce DM, Kernan N, Scaradavou A, Giralt SA, Papadopoulos EB, Politikos I.

Blood Adv. 2019 Apr 9;3(7):939-944. doi: 10.1182/bloodadvances.2018028662.

25.

Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma.

Dahi PB, Moskowitz CH, Giralt SA, Lazarus HM.

Expert Rev Hematol. 2019 Jun;12(6):407-418. doi: 10.1080/17474086.2019.1596793. Epub 2019 May 17.

PMID:
30884247
26.

Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma.

Dahi PB, Moskowitz CH, Giralt SA, Lazarus HM.

Expert Rev Hematol. 2019 Apr;12(4):255-264. doi: 10.1080/17474086.2019.1593135. Epub 2019 Mar 21.

PMID:
30874456
27.

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC.

Leukemia. 2019 Apr;33(4):1058-1059. doi: 10.1038/s41375-019-0410-3.

PMID:
30842604
28.

Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation.

Scordo M, Bhatt V, Hilden P, Smith M, Thoren K, Cho C, Shah GL, Maloy MA, Papadopoulos EB, Jakubowski AA, Avecilla ST, O'Reilly RJ, Castro-Malaspina H, Tamari R, Shaffer BC, Boelens JJ, Perales MA, Giralt SA.

Biol Blood Marrow Transplant. 2019 Aug;25(8):1526-1535. doi: 10.1016/j.bbmt.2019.02.021. Epub 2019 Mar 1.

PMID:
30831208
29.

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).

Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J.

Lancet Haematol. 2019 Mar;6(3):e132-e143. doi: 10.1016/S2352-3026(18)30221-7.

PMID:
30824040
30.

The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG).

Kyriakou C, Molloy S, Vrionis F, Alberico R, Bastian L, Zonder JA, Giralt S, Raje N, Kyle RA, Roodman DGD, Dimopoulos MA, Rajkumar SV, Durie BBG, Terpos E.

Blood Cancer J. 2019 Feb 26;9(3):27. doi: 10.1038/s41408-019-0187-7.

31.

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.

Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A.

J Clin Oncol. 2019 Mar 1;37(7):589-597. doi: 10.1200/JCO.18.00685. Epub 2019 Jan 17.

32.

Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.

Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Maloy M, Castro-Malaspina H, Giralt SA, Weinberg RS, Mascarenhas JO, Mesa R, Rondelli D, Dueck AC, Levine RL, Gupta V, Hoffman R, Rampal RK.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1142-1151. doi: 10.1016/j.bbmt.2019.01.002. Epub 2019 Jan 6.

PMID:
30625392
33.

Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation.

Scordo M, Hsu M, Jakubowski AA, Shah GL, Cho C, Maloy MA, Avecilla ST, Papadopoulos EB, Gyurkocza B, Castro-Malaspina H, Tamari R, O'Reilly RJ, Perales MA, Giralt SA, Shaffer BC.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1136-1141. doi: 10.1016/j.bbmt.2018.12.842. Epub 2019 Jan 6.

PMID:
30625387
34.

Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults.

Lin RJ, Hilden PD, Elko TA, Dahi PB, Shahrokni A, Jakubowski AA, Perales MA, Sauter CS, Castro-Malaspina HR, Barker JN, Shaffer BC, Tamari R, Papadopoulos EB, Maloy MA, Korc-Grodzicki B, Giralt SA.

Blood Adv. 2019 Jan 8;3(1):12-20. doi: 10.1182/bloodadvances.2018028241.

35.

Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia.

Xiao W, Goldberg AD, Famulare CA, Devlin SM, Nguyen NT, Sim S, Kabel CC, Patel MA, McGovern EM, Patel A, Schulman J, Dunbar AJ, Epstein-Peterson ZD, Menghrajani KN, Getta BM, Cai SF, Geyer MB, Glass JL, Taylor J, Viny AD, Levine RL, Zhang Y, Giralt SA, Klimek V, Tallman MS, Roshal M.

Haematologica. 2019 Jul;104(7):1378-1387. doi: 10.3324/haematol.2018.203018. Epub 2018 Dec 6.

36.

Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.

Lin RJ, Ho C, Hilden PD, Barker JN, Giralt SA, Hamlin PA, Jakubowski AA, Castro-Malaspina HR, Robinson KS, Papadopoulos EB, Perales MA, Sauter CS.

Br J Haematol. 2019 Mar;184(6):1006-1010. doi: 10.1111/bjh.15721. Epub 2018 Dec 11.

PMID:
30537212
37.

PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation.

Xiao W, Bharadwaj M, Levine M, Farnhoud N, Pastore F, Getta BM, Hultquist A, Famulare C, Medina JS, Patel MA, Gao Q, Lewis N, Pichardo J, Baik J, Shaffer B, Giralt S, Rampal R, Devlin S, Cimera R, Zhang Y, E Arcila M, Papaemmanuil E, Levine RL, Roshal M.

Blood Adv. 2018 Dec 11;2(23):3526-3539. doi: 10.1182/bloodadvances.2018023531. Erratum in: Blood Adv. 2019 Apr 9;3(7):956.

38.

Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients.

Giralt S, Seifter E.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):103-109. doi: 10.1182/asheducation-2018.1.103. Review.

39.

Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes.

Huang YT, Su Y, Kim SJ, Nichols P, Burack D, Maloy M, Giralt S, Perales MA, Jakubowski AA, Papanicolaou GA.

Biol Blood Marrow Transplant. 2019 Apr;25(4):791-799. doi: 10.1016/j.bbmt.2018.11.012. Epub 2018 Nov 24.

PMID:
30476551
40.

The timing and widespread effects of the largest Holocene volcanic eruption in Antarctica.

Antoniades D, Giralt S, Geyer A, Álvarez-Valero AM, Pla-Rabes S, Granados I, Liu EJ, Toro M, Smellie JL, Oliva M.

Sci Rep. 2018 Nov 22;8(1):17279. doi: 10.1038/s41598-018-35460-x.

41.

Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma.

Dahi PB, Lazarus HM, Sauter CS, Giralt SA.

Bone Marrow Transplant. 2019 Jul;54(7):943-960. doi: 10.1038/s41409-018-0378-z. Epub 2018 Nov 2. Review.

PMID:
30390059
42.

Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC.

Malard F, Labopin M, Cho C, Blaise D, Papadopoulos EB, Passweg J, O'Reilly R, Forcade E, Maloy M, Volin L, Castro-Malaspina H, Hicheri Y, Jakubowski AA, Orvain C, Giralt S, Mohty M, Nagler A, Perales MA.

J Hematol Oncol. 2018 Oct 20;11(1):127. doi: 10.1186/s13045-018-0668-3.

43.

Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant.

Taur Y, Coyte K, Schluter J, Robilotti E, Figueroa C, Gjonbalaj M, Littmann ER, Ling L, Miller L, Gyaltshen Y, Fontana E, Morjaria S, Gyurkocza B, Perales MA, Castro-Malaspina H, Tamari R, Ponce D, Koehne G, Barker J, Jakubowski A, Papadopoulos E, Dahi P, Sauter C, Shaffer B, Young JW, Peled J, Meagher RC, Jenq RR, van den Brink MRM, Giralt SA, Pamer EG, Xavier JB.

Sci Transl Med. 2018 Sep 26;10(460). pii: eaap9489. doi: 10.1126/scitranslmed.aap9489.

44.

Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample Database.

Liu Y, Han H, Shah G, Giralt S, Ola Landgren C, He J, Lesokhin AM.

Biol Blood Marrow Transplant. 2019 Jan;25(1):41-46. doi: 10.1016/j.bbmt.2018.08.030. Epub 2018 Sep 6.

45.

End-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer center.

Lin RJ, Elko TA, Perales MA, Alexander K, Jakubowski AA, Devlin SM, Dahi PB, Papadopoulos EB, Klimek VM, Giralt SA, Nelson JE.

Bone Marrow Transplant. 2019 May;54(5):700-706. doi: 10.1038/s41409-018-0311-5. Epub 2018 Aug 22.

46.

Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation.

Rondon-Clavo C, Scordo M, Hilden P, Shah GL, Cho C, Maloy MA, Papadopoulos EB, Jakubowski AA, O'Reilly RJ, Gyurkocza B, Castro-Malaspina H, Tamari R, Shaffer BC, Perales MA, Jaimes EA, Giralt SA.

Biol Blood Marrow Transplant. 2018 Dec;24(12):2517-2522. doi: 10.1016/j.bbmt.2018.07.031. Epub 2018 Jul 26.

47.

CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.

de Lima M, Oran B, Champlin RE, Papadopoulos EB, Giralt SA, Scott BL, William BM, Hetzer J, Laille E, Hubbell B, Skikne BS, Craddock C.

Biol Blood Marrow Transplant. 2018 Oct;24(10):2017-2024. doi: 10.1016/j.bbmt.2018.06.016. Epub 2018 Jun 20.

48.

Prevalence, risk factors, and psychosocial adjustment of problematic gambling in adolescents: Results from two representative German samples.

Giralt S, Müller KW, Beutel ME, Dreier M, Duven E, Wölfling K.

J Behav Addict. 2018 Jun 1;7(2):339-347. doi: 10.1556/2006.7.2018.37. Epub 2018 Jun 5.

49.

Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation.

Scordo M, Morjaria SM, Littmann ER, Bhatia A, Chung HH, Maloy M, DeAngelis LM, Giralt SA, Taur Y, Sauter CS.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1914-1919. doi: 10.1016/j.bbmt.2018.04.013. Epub 2018 Apr 18.

50.

Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients.

Kim SJ, Huang YT, Foldi J, Lee YJ, Maloy M, Giralt SA, Jakubowski AA, Papanicolaou GA.

Transpl Infect Dis. 2018 Jun;20(3):e12881. doi: 10.1111/tid.12881. Epub 2018 Apr 10.

Supplemental Content

Loading ...
Support Center